-
1.发明申请
公开(公告)号：WO1992020427A1
公开(公告)日：1992-11-26
申请号：PCT/US1992003476
申请日：1992-04-27
Applicant: BAXTER INTERNATIONAL INC.
Inventor： BAXTER INTERNATIONAL INC. , STEWART, Mary, A. , JOHNSON, Kenneth, M.
IPC: B01D37/00
CPC classification number: A61M1/0209 , A61M1/0222 , A61M2202/0427 , A61M2202/0429 , A61M2202/0439 , A61M2202/0057 , A61M2202/0042
Abstract: Systems and methods of collecting blood cells use a first container (16) connected to initially collect blood. A filtration system (14) is provided that uses two flow paths (34, 38), the first (38) being a dual purpose path that is initially used to convey plasma and platelets to a pair of transfer/storage containers (30, 32). A second flow path (34) leads to a temporary transfer container (28) through a filtration device (36). The dual purpose fluid path (38) is next used to convey blood cells, not substantially free of undesired matter, from the temporary storage container (28) to a storage container (18). The filtration system (14) is then detached from the blood collection system (12).
Abstract translation: 用于收集血细胞的系统和方法，使用与最初收集血液相连的第一容器（16）。 过滤系统（14）利用两个流动路径（34,38），第一个（38）是最初用于将血浆和血小板运送到一对存储/转移容器（30,32）的二价轨道。 ）。 第二流动路径（34）通向过滤装置（36）的临时输送容器（28）。 然后使用二价液体路径（38）将基本上不含有不需要的物质的血细胞从临时储存容器（28）输送到储存容器（18）。 然后将过滤系统（14）从血液收集系统（12）分离。
-
公开(公告)号：WO1996018292A1
公开(公告)日：1996-06-20
申请号：PCT/US1995010705
申请日：1995-08-22
Applicant: BAXTER INTERNATIONAL INC.
Inventor： BAXTER INTERNATIONAL INC. , GRODE, Gerald, A. , STEWART, Mary, A.
IPC: A01N01/02
CPC classification number: A61K35/14
Abstract: A new citrate-based anticoagulant for donor whole blood provides good platelet yield and cell morphology at a significantly reduced risk of donor paresthesia during apheresis procedures. The primary citrate anticoagulant compositions include a citric acid to total citrate ration greater than about 30 %. The anticoagulants are mixed with whole blood to provide an anticoagulated blood mixture which contains a citric acid concentration of greater than about 5.0 mM, a total citrate concentration of less than about 20 mM, and an initial blood pH of less than about 6.75. The platelet rich products including PRP and PC prepared from blood collected in accordance with the invention exhibit better platelet yields and better platelet morphology on storage.
Abstract translation: 用于供体全血的新的基于柠檬酸盐的抗凝剂在分离术期间以显着降低的供体感觉异常风险提供良好的血小板产生和细胞形态。 主要的柠檬酸盐抗凝剂组合物包括柠檬酸至总柠檬酸盐比例大于约30％。 将抗凝剂与全血混合以提供含有大于约5.0mM的柠檬酸浓度，小于约20mM的总柠檬酸盐浓度和小于约6.75的初始血液pH的抗凝血液混合物。 包含根据本发明收集的血液制备的包含PRP和PC的富血小板产品在储存时表现出更好的血小板产量和更好的血小板形态。
-
3.发明申请
公开(公告)号：WO1991008820A1
公开(公告)日：1991-06-27
申请号：PCT/US1990006924
申请日：1990-11-28
Applicant: BAXTER INTERNATIONAL INC.
Inventor： BAXTER INTERNATIONAL INC. , STEWART, Mary, A.
IPC: B01D37/00
CPC classification number: A61M1/0222 , A61M1/0231 , A61M2202/0427 , A61M2202/0429 , A61M2202/0439 , A61M2202/005 , A61M2202/0042
Abstract: Systems and methods of collecting blood cells, substantially free of undesired matter, use a first container (16), that forms a part of blood collection system (10), to initially collect a quantity of blood cells. A filtration system (14) is then attached to the first container. The filtration system (14) includes a second container (34), a first fluid path (36) that leads to the second container (34) through a filtration device (40), and a second fluid path (38) that leads to the second container (34) bypassing the filtration device (40). Blood cells are conveyed from the first container (16) through the first fluid path (36) and filtration device (40) and into the second container (34) to separate the undesired matter from blood cells. Blood cells, now substantially free of the undesired matter, are then conveyed from the second container (34) through the second fluid path (38), bypassing the filtration device (40), and back into the first container (16). The filtration system (14) is then detached from the blood collection system (10).
-
公开(公告)号：EP0458944A1
公开(公告)日：1991-12-04
申请号：EP91901424.0
申请日：1990-11-28
Applicant: BAXTER INTERNATIONAL INC.
Inventor： STEWART, Mary, A.
CPC classification number: A61M1/0222 , A61M1/0231 , A61M2202/0427 , A61M2202/0429 , A61M2202/0439 , A61M2202/005 , A61M2202/0042
Abstract: Systèmes et procédés de récupération de cellules sanguines, sensiblement exemptes de substances indésirées, utilisant un premier conteneur (16) qui forme une partie du système de récupération de sang (10) pour récupérer une quantité de cellules sanguines. Un système de filtration (14) est ensuite fixé à ce premier conteneur. Le système de filtration (14) comprend un second conteneur (34), un premier chemin de fluide (36) qui mène au second conteneur (34) au travers d'un dispositif de filtration (40) et un second cheminement de fluide (38) qui mène au second conteneur (34) en bypassant le dispositif de filtration (40). Les cellules sanguines sont acheminées depuis le premier conteneur (16) au travers du premier chemin de fluide (36) et du dispositif de filtration (40) pour arriver dans le second conteneur (34) et séparer les substances indésirées des cellules sanguines. Les cellules sanguines exemptes de substances indésirées sont alors acheminées depuis le second conteneur (34) en passant par le second chemin de fluide (38), en bypassant le dispositif de filtration (34) pour revenir dans le premier conteneur (16). Le système de filtration (14) est ensuite détaché du système récupérateur de sang (10).
-
Patent Agency Ranking
公开(公告)号：EP0540731B1
公开(公告)日：1997-01-15
申请号：EP92913358.5
申请日：1992-04-27
Applicant: BAXTER INTERNATIONAL INC.
Inventor： STEWART, Mary, A. , JOHNSON, Kenneth, M.
CPC classification number: A61M1/0209 , A61M1/0222 , A61M2202/0427 , A61M2202/0429 , A61M2202/0439 , A61M2202/0057 , A61M2202/0042
Abstract: Systems and methods of collecting blood cells use a first container (16) connected to initially collect blood. A filtration system (14) is provided that uses two flow paths (34, 38), the first (38) being a dual purpose path that is initially used to convey plasma and platelets to a pair of transfer/storage containers (30, 32). A second flow path (34) leads to a temporary transfer container (28) through a filtration device (36). The dual purpose fluid path (38) is next used to convey blood cells, not substantially free of undesired matter, from the temporary storage container (28) to a storage container (18). The filtration system (14) is then detached from the blood collection system (12).
-
公开(公告)号：EP0540731A1
公开(公告)日：1993-05-12
申请号：EP92913358.0
申请日：1992-04-27
Applicant: BAXTER INTERNATIONAL INC.
Inventor： STEWART, Mary, A. , JOHNSON, Kenneth, M.
CPC classification number: A61M1/0209 , A61M1/0222 , A61M2202/0427 , A61M2202/0429 , A61M2202/0439 , A61M2202/0057 , A61M2202/0042
Abstract: Systèmes et procédés destinés à recueillir des cellules sanguines, utilisant un premier récipient (16) relié de manière à collecter initialement du sang. Un système de filtration (14) utilise deux trajectoires d'écoulement (34, 38), la première (38) étant une trajectoire bivalente utilisée intialement pour transporter du plasma et des plaquettes à une paire de récipients de stockage/transfert (30, 32). Une seconde trajectoire découlement (34) conduit à un récipient de transfert temporaire (28) en passant par un dispositif de filtration (36). La trajectoire de liquide bivalente (38) est ensuite utilisée pour transporter des cellules sanguines, qui ne sont pas pratiquement exemptes de matériaux non désirés, du récipient de stockage temporaire (28) à un récipient de stockage (18). Le système de filtration (14) est ensuite détaché du système de collecte de sang (12).
-
公开(公告)号：EP0744892B1
公开(公告)日：2003-12-03
申请号：EP95929639.3
申请日：1995-08-22
Applicant: BAXTER INTERNATIONAL INC.
Inventor： GRODE, Gerald, A. , STEWART, Mary, A.
CPC classification number: A61K35/14
Abstract: A new citrate-based anticoagulant for donor whole blood provides good platelet yield and cell morphology at a significantly reduced risk of donor paresthesia during apheresis procedures. The primary citrate anticoagulant compositions include a citric acid to total citrate ratio greater than about 30%. The anticoagulants are mixed with whole blood to provide an anticoagulated blood mixture which contains a citric acid concentration of greater than about 5.0 mM, a total citrate concentration of less than about 20 mM, and an initial blood pH of less than about 6.75. The platelet rich products including PRP and PC prepared from blood collected in accordance with the invention exhibit better platelet yields and better platelet morphology on storage.
-
公开(公告)号：EP0744892A1
公开(公告)日：1996-12-04
申请号：EP95929639.0
申请日：1995-08-22
Applicant: BAXTER INTERNATIONAL INC.
Inventor： GRODE, Gerald, A. , STEWART, Mary, A.
CPC classification number: A61K35/14
Abstract: A new citrate-based anticoagulant for donor whole blood provides good platelet yield and cell morphology at a significantly reduced risk of donor paresthesia during apheresis procedures. The primary citrate anticoagulant compositions include a citric acid to total citrate ratio greater than about 30%. The anticoagulants are mixed with whole blood to provide an anticoagulated blood mixture which contains a citric acid concentration of greater than about 5.0 mM, a total citrate concentration of less than about 20 mM, and an initial blood pH of less than about 6.75. The platelet rich products including PRP and PC prepared from blood collected in accordance with the invention exhibit better platelet yields and better platelet morphology on storage.
-
公开(公告)号：EP0458944B1
公开(公告)日：1996-06-05
申请号：EP91901424.1
申请日：1990-11-28
Applicant: BAXTER INTERNATIONAL INC.
Inventor： STEWART, Mary, A.
IPC: A61J1/00
CPC classification number: A61M1/0222 , A61M1/0231 , A61M2202/0427 , A61M2202/0429 , A61M2202/0439 , A61M2202/005 , A61M2202/0042
Abstract: Systems and methods of collecting blood cells, substantially free of undesired matter, use a first container (16), that forms a part of blood collection system (10), to initially collect a quantity of blood cells. A filtration system (14) is then attached to the first container. The filtration system (14) includes a second container (34), a first fluid path (36) that leads to the second container (34) through a filtration device (40), and a second fluid path (38) that leads to the second container (34) bypassing the filtration device (40). Blood cells are conveyed from the first container (16) through the first fluid path (36) and filtration device (40) and into the second container (34) to separate the undesired matter from blood cells. Blood cells, now substantially free of the undesired matter, are then conveyed from the second container (34) through the second fluid path (38), bypassing the filtration device (40), and back into the first container (16). The filtration system (14) is then detached from the blood collection system (10).
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.025 seconds)
